rank,ticker,company_name,ai_score,sentiment,recommendation,catalysts,risks,certainty,articles_count,quant_alpha,current_price,price_timestamp,entry_zone_low,entry_zone_high,target_conservative,target_aggressive,stop_loss,fundamental_adjustment,quarterly_earnings_growth_yoy,annual_earnings_growth_yoy,profit_margin_pct,debt_to_equity,is_profitable,net_worth_positive,financial_health_status,headline,reasoning
1,RELIANCE,RELIANCE INDUSTRIES LIMITED,69.1,neutral,HOLD,,"News is purely CSR/philanthropy with no business impact, No connection to company's financial performance or operations, Event unrelated to revenue, earnings, or business strategy, Overbought stocks (RSI>70) historically have 0% success rate in this system",85,4,51.6,1496.50,2025-11-10T11:47:46.019444,1474.05,1503.98,1533.91,1571.33,1459.09,+7.46,78.32,0.04,11.08,0.44,TRUE,TRUE,healthy,Reliance Chairman Mukesh Ambani donates  ₹15 crore to Guruvayur Devaswom for new hospital project in,"This is a CSR/philanthropy news item about Mukesh Ambani's ₹15 crore personal donation for a hospital project and temple visit. While the news is confirmed (85% certainty from Livemint/ANI), it has ze"
2,SYNGENE,SYNGENE INTERNATIONAL LIMITED,66.9,bullish,HOLD,"clinical_trials_expansion, biotech_funding_recovery, facility_operationalization, us_acquisition","Near-term profitability pressured by depreciation from new biologics facility, Inventory adjustment headwinds with large molecule customer continuing for next few quarters, Q2 FY26 net profit declined 37% YoY to ₹67cr despite 2% revenue growth, New US facility (Bayview) not operational until H2 FY26, Stock in downtrend: -2.4% below 20/50 DMA, -4.5% 10-day momentum, weak volume (0.37x)",72,1,33.1,628.10,2025-11-10T11:48:41.637186,621.82,628.10,653.22,678.35,602.98,+3.12,14.53,-2.71,9.91,0.12,TRUE,TRUE,moderate,"Syngene eyes growth tailwinds from global trial wins, biotech funding recovery: CEO","Syngene secured its first global Phase 3 clinical trial (major milestone for late-stage trial capabilities) and acquired US biologics facility for $36.5M (₹274cr), signaling strategic expansion. CEO c"
3,TRIDENT,TRIDENT LIMITED,55.4,neutral,HOLD,expansion,"Wrong company ticker - news about Trident Realty, not TRIDENT (textile/paper company), Complete sector mismatch - real estate vs manufacturing, News has zero relevance to stock being analyzed, Weak technicals: RSI 51, price below 20DMA and 50DMA, declining momentum, Low volume (0.25x average) indicates lack of buying interest",95,1,43.6,27.99,2025-11-10T11:36:55.940619,27.57,28.13,28.69,29.39,27.29,+7.84,89.83,5.83,8.20,0.35,TRUE,TRUE,healthy,"Trident Realty targets ₹1,200 crore revenue from sale of 199 plots at Panchkula","This news is about Trident Realty (real estate developer), NOT TRIDENT stock (textile/paper manufacturer). Complete ticker mismatch - the ₹1,200 crore project has ZERO impact on the stock being analyz"
4,TRENT,TRENT LIMITED,53.8,bearish,HOLD,"earnings, weak_sssg, store_expansion","Stock declined 6.4% despite 11% profit growth - negative market reaction, Same-store sales growth (SSSG) declined to low single digits for first time in 3+ years, Sequential revenue decline Q2 vs Q1 (₹4,818cr vs ₹4,883cr), Extremely oversold RSI at 15.34 suggests further downside momentum, Price 8.4% below 20DMA and 12.1% below 50DMA - strong downtrend, Weak demand environment and unseasonal rains dampening consumer sentiment, HDFC Securities maintains REDUCE rating with TP ₹4,300 (0.3% downside from current), Requires 29%+ revenue growth in H2 FY26 to meet consensus - very high ask rate",85,1,37.1,4313.00,2025-11-10T11:49:40.065553,4248.31,4334.56,4420.82,4528.65,4205.18,+5.80,9.45,4.03,8.80,0.41,TRUE,TRUE,healthy,Trent shares decline 6% after reporting Q2 results. Should you buy? ,"Despite 11% YoY profit growth and 16% revenue growth in Q2, the stock declined 6.4% indicating negative market reception. Critical red flags: SSSG fell to low single digits (first time in 3+ years), s"
5,BSE,BSE LIMITED,45.5,neutral,HOLD,,"News about Lenskart IPO listing, not directly about BSE operations, BSE mentioned only as listing venue, no fundamental impact, Lenskart's subdued debut (listed below IPO price) reflects negative market sentiment, No revenue, profit, or operational news for BSE itself",85,2,77.4,2674.20,2025-11-10T11:42:42.593798,2634.09,2687.57,2741.05,2807.91,2607.34,+9.26,103.51,70.34,56.28,0.00,TRUE,TRUE,healthy,"Lenskart Share Price Listing Live: Shares list below ₹402-IPO price on NSE, BSE","This article is about Lenskart's IPO listing on BSE/NSE exchanges, not about BSE Ltd's business operations. While BSE benefits marginally from listing fees, this is routine operational activity with n"
